A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer

This study tests whether adding an immunotherapy drug called cadonilimab (AK104) to standard chemoradiation (chemotherapy plus radiation) improves outcomes for women with locally advanced cervical cancer (stage III–IVA) who cannot have surgery. The treatment combines radiation, chemotherapy, and immune checkpoint blockade. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have confirmed cervical cancer (squamous cell, adenocarcinoma, or adenosquamous) at stage III or IVA - Your cancer cannot be surgically removed - You have not received any prior treatment for this cancer - You are in good physical condition (ECOG 0 or 1) - You have adequate organ function **You may NOT be eligible if...** - You have cancer that has spread beyond the pelvis (distant metastases) - You have received prior chemotherapy, radiation, or immunotherapy for this cancer - You have active autoimmune disease or are taking immune-suppressing medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.